| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | ANGION BIOMEDICA CORP. | 456 MONTGOMERY ST STE 1200 | SAN FRANCISCO | CA | 94104-1264 | SAN FRANCISCO | USA | R43DK121642 | Targeted Therapeutics for Liver Disease | 000 | 1 | NIH | 5/27/2021 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $220,731 ) |
| | 2019 | 2019 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R43DK121642 | Targeted Therapeutics for Liver Disease | 000 | 1 | NIH | 3/18/2019 | $220,731 |
| | 2019 | 2017 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R43DK116404 | Steroid 11?-hydroxylase inhibitor for Cushing's Syndrome | 000 | 1 | NIH | 1/18/2019 | $0 |
| | 2019 | 2017 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R43DK116452 | ROCK2 selective inhibitor for Chronic Kidney Disease | 000 | 1 | NIH | 1/28/2019 | $0 |
| | 2019 | 2017 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R44DK095625 | Aldosterone Synthase Inhibitor for CKD | 000 | 3 | NIH | 7/5/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,151,356 ) |
| | 2017 | 2017 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R44DK095625 | Aldosterone Synthase Inhibitor for CKD | 000 | 3 | NIH | 4/1/2017 | $709,140 |
| | 2017 | 2017 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R43DK116404 | Steroid 11?-hydroxylase inhibitor for Cushing's Syndrome | 000 | 1 | NIH | 9/14/2017 | $222,670 |
| | 2017 | 2017 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R43DK116452 | ROCK2 selective inhibitor for Chronic Kidney Disease | 000 | 1 | NIH | 9/14/2017 | $219,546 |
| | 2017 | 2014 | ANGION BIOMEDICA CORP. | 51 CHARLES LINDBERGH BLVD | UNIONDALE | NY | 11553-3658 | NASSAU | USA | R44DK085771 | PDGFR and KDR Inhibitors for Liver Fibrosis | 000 | 2 | NIH | 2/14/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $610,943 ) |
| | 2016 | 2016 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44DK095625 | Aldosterone Synthase Inhibitor for CKD | 000 | 2 | NIH | 3/17/2016 | $610,943 |
|
| Issue Date FY: 2014 ( Subtotal = $2,878,375 ) |
| | 2014 | 2014 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44AR058041 | Anti-Fibrotic Therapy for Scleroderma/SSc | 000 | 4 | NIH | 4/30/2014 | $1,584,102 |
| | 2014 | 2014 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43AI110004 | A Therapeutic for Radiation Induced Lung Injury | 000 | 1 | NIH | 5/15/2014 | $299,948 |
| | 2014 | 2014 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44DK085771 | PDGFR and KDR Inhibitors for Liver Fibrosis | 000 | 2 | NIH | 9/8/2014 | $769,978 |
| | 2014 | 2014 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43AA023432 | A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis | 000 | 1 | NIH | 9/17/2014 | $224,347 |
|
| Issue Date FY: 2013 ( Subtotal = $3,351,210 ) |
| | 2013 | 2013 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43AA021054 | LPA1 ANTAGONIST FOR ALCOHOLIC LIVER DISEASE | 000 | 1 | NIH | 9/26/2013 | $251,048 |
| | 2013 | 2013 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44DK085841 | ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE | 001 | 3 | NIH | 8/22/2013 | $1,002,967 |
| | 2013 | 2013 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44AA020163 | A NOVEL THERAPEUTIC FOR LIVER FIBROSIS | 000 | 3 | NIH | 8/19/2013 | $1,038,130 |
| | 2013 | 2013 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43DK095625 | ALDOSTERONE SYNTHASE INHIBITOR FOR CKD | 000 | 1 | NIH | 6/18/2013 | $380,911 |
| | 2013 | 2013 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44AR058041 | Anti-Fibrotic Therapy for Scleroderma/SSc | 000 | 3 | NIH | 4/23/2013 | $619,112 |
| | 2013 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44DK085841 | ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE | 000 | 2 | NIH | 8/1/2013 | $59,042 |
| | 2013 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44HL091699 | A PILOT CLINICAL STUDY IN ACUTE STEMI | 000 | 3 | NIH | 8/8/2013 | $0 |
| | 2013 | 2010 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44DK066654 | PILOT CLINICAL STUDY IN RENAL TRANSPLANTATION | 000 | 6 | NIH | 7/31/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $6,529,620 ) |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44DK085841 | ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE | 000 | 2 | NIH | 7/26/2012 | $843,452 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43HL114298 | AN INNOVATIVE CARDIOPROTECTIVE | 000 | 1 | NIH | 4/4/2012 | $373,934 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44DK085841 | ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE | 001 | 2 | NIH | 8/6/2012 | -$843,452 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44DK085841 | ANTIFIBROTIC THERAPY FOR CHRONIC KIDNEY DISEASE | 001 | 2 | NIH | 8/6/2012 | $843,452 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44NS045373 | NOVEL NEUROPROTECTIVE/RESTORATIVE THERAPY FOR ISCHEMIC STROKE | 000 | 4 | NIH | 7/31/2012 | $1,194,283 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43AR063149 | RETINOIC ACID MODULATION FOR SCLERODERMA | 000 | 1 | NIH | 7/20/2012 | $298,114 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44DK078455 | UNIQUE CLINICAL STUDY ON DGF USING PAIRED KIDNEYS | 000 | 3 | NIH | 3/28/2012 | $664,710 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43HL112415 | LPA ANTAGONISTS FOR THE TREATMENT OF IPF | 000 | 1 | NIH | 7/31/2012 | $354,104 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44AR058041 | Anti-Fibrotic Therapy for Scleroderma/SSc | 000 | 2 | NIH | 5/7/2012 | $606,272 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44AA020163 | A NOVEL THERAPEUTIC FOR LIVER FIBROSIS | 000 | 2 | NIH | 9/18/2012 | $971,501 |
| | 2012 | 2012 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44AA019876 | TREATMENT FOR ALCOHOLIC LIVER DISEASE | 000 | 3 | NIH | 8/16/2012 | $1,223,250 |
| | 2012 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44DK085781 | PHASE I CLINICAL STUDY USING AN ANTIFIBROTIC DRUG | 000 | 2 | NIH | 3/5/2012 | $0 |
| | 2012 | 2010 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44AA015223 | SAFETY AND PK STUDY IN HEPATIC IMPAIRMENT PATIENTS | 000 | 5 | NIH | 8/29/2012 | $0 |
| | 2012 | 2010 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44DK066654 | PILOT CLINICAL STUDY IN RENAL TRANSPLANTATION | 000 | 6 | NIH | 5/24/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $4,012,311 ) (Continued on the next page) |
| | 2011 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44DK085781 | PHASE I CLINICAL STUDY USING AN ANTIFIBROTIC DRUG | 000 | 2 | NIH | 2/18/2011 | $764,642 |
| | 2011 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44AA019876 | TREATMENT FOR ALCOHOLIC LIVER DISEASE | 000 | 2 | NIH | 9/12/2011 | $829,090 |
| | 2011 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44DK078455 | UNIQUE CLINICAL STUDY ON DGF USING PAIRED KIDNEYS | 001 | 2 | NIH | 6/9/2011 | $0 |
| | 2011 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R43AA020163 | A NOVEL THERAPEUTIC FOR LIVER FIBROSIS | 000 | 1 | NIH | 9/16/2011 | $269,158 |
| | 2011 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | NASSAU | USA | R44DK085781 | PHASE I CLINICAL STUDY USING AN ANTIFIBROTIC DRUG | 002 | 2 | NIH | 3/1/2011 | $0 |
| | 2011 | 2011 | ANGION BIOMEDICA CORPORATION | 350 COMMUNITY DRIVE | MANHASSET | NY | 11030-3816 | NASSAU | USA | R44HL091699 | A PILOT CLINICAL STUDY IN ACUTE STEMI | 000 | 3 | NIH | 8/5/2011 | $1,484,711 |
|
